监管与产业情报（Pharma-Intel）· Medical Xpress - Medications·2026-09-30 21:00· 3 天前精选评分62

petrelintide二期ZUPREME 1试验：每周注射42周减重约10%，胃肠道永久停药率1.5%

Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies

导读

petrelintide每周注射在ZUPREME 1二期试验中42周减重约10%，胃肠道永久停药率仅1.5%，结果于EASD年会公布并发表于The Lancet Diabetes & Endocrinology。

推荐理由

原文给出42周各剂量减重幅度与胃肠道停药率，读者可与GLP-1类真实世界停药数据直接比较。